Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
Résumé
Therapeutic monoclonal anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies are associated with immune-mediated enterocolitis. The aim of this study was to provide a detailed description of this entity. We included patients with endoscopic signs of inflammation after anti-CTLA-4 infusions for cancer treatment. Other causes of enterocolitis were excluded. Clinical, biological and endoscopic data were recorded. A single pathologist reviewed endoscopic biopsies and colectomy specimens from 27 patients. Patients with and without enterocolitis after ipilimumab-treated melanoma were compared, to identify clinical factors associated with enterocolitis. Thirty-nine patients with anti-CTLA-4 enterocolitis were included (ipilimumab
Domaines
Sciences du Vivant [q-bio]NGERE UL : Connectez-vous pour contacter le contributeur
https://hal.univ-lorraine.fr/hal-01659102
Soumis le : vendredi 8 décembre 2017-10:08:31
Dernière modification le : samedi 20 avril 2024-03:20:39
Dates et versions
Identifiants
- HAL Id : hal-01659102 , version 1
- DOI : 10.1093/ecco-jcc/jjv227
- PUBMEDCENTRAL : PMC4946758
Citer
L. Marthey, C. Mateus, C. Mussini, M. Nachury, S. Nancey, et al.. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10 (4), pp.395-401. ⟨10.1093/ecco-jcc/jjv227⟩. ⟨hal-01659102⟩
Collections
100
Consultations
0
Téléchargements